Showing results (351-360 of 382) with videos related to
Sort By:
Pageof 39
European Urology|August 20, 2020
Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term SurvivorsKarim Fizazi, Charles G Drake, Tomasz M Beer, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 9, 2017
Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical TrialChanning J Paller, Xian C Zhou, Elisabeth I Heath, et al.European Journal of Cancer (Oxford, England : 1990)|November 30, 2021
Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findingsUrsula M Vogl, Tomasz M Beer, Ian D Davis, et al.Science (New York, N.Y.)|January 6, 2018
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinomaDiana Miao, Claire A Margolis, Wenhua Gao, et al.Medrxiv : the Preprint Server for Health Sciences|September 24, 2024
Fc-enhanced anti-CTLA-4 depletes tumor-infiltrating regulatory T cells to augment immune effects of androgen ablation in high-risk prostate cancerCasey R Ager, Aleksandar Obradovic, Patrick McCann, et al.Cancer Discovery|January 28, 2021
An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor GrowthHubert Lam, Lisa K McNeil, Hanna Starobinets, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 2016
Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine GliomasJennifer E Kim, Mira A Patel, Antonella Mangraviti, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2016
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell CarcinomaToni K Choueiri, Mayer N Fishman, Bernard Escudier, et al.Nature Medicine|April 3, 2023
Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trialEugene Shenderov, Angelo M De Marzo, Tamara L Lotan, et al.The Lancet. Oncology|May 17, 2014
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trialEugene D Kwon, Charles G Drake, Howard I Scher, et al.Pageof 39